KU Leuven

ImCyse SA is a clinical-stage biopharmaceutical company based in Liège, Belgium, that specializes in developing active immunotherapies aimed at treating and preventing severe chronic autoimmune diseases linked to immune system disruptions. Founded in 2010, ImCyse utilizes a unique technology platform that focuses on the administration of Imotopes™, specifically modified peptides that generate cytolytic CD4 T-cells. These T-cells selectively eliminate antigen-presenting cells and autoantigen-specific lymphocytes, targeting the underlying causes of diseases like type 1 diabetes and multiple sclerosis. ImCyse's innovative approach not only aims to provide therapeutic alternatives where none exist but also seeks to cure patients without compromising their immune defenses. The company has demonstrated proof of concept across several indications and has successfully completed its first clinical trial for type 1 diabetes, yielding promising results while developing additional Imotopes™ for various autoimmune conditions.

reMYND NV is a biotechnology company based in Leuven, Belgium, focused on developing disease-modifying treatments for Alzheimer’s, Parkinson’s, diabetes, and other protein-misfolding disorders. The company is advancing several investigational compounds, including ReS19-T for Alzheimer’s and ReS39 for diabetes, as well as ReS3-T, which targets neuronal hyperactivity associated with Alzheimer’s and epilepsy. Additionally, reMYND operates a phenotypic screening platform aimed at discovering small molecule treatments that mitigate the toxicity of misfolded proteins such as Tau and Synuclein. The company also functions as a contract research organization (CRO), providing services that assess the in-vivo characteristics and effects of experimental therapies using proprietary mouse models. This CRO capability has enabled reMYND to support various pharmaceutical clients, including major companies in the United States, Europe, and Japan, by delivering critical proof-of-concept data for drugs in clinical development. Established in 2002, reMYND is committed to addressing the challenges posed by protein misfolding diseases through innovative research and development.

Montis Biosciences is a biotechnology company based in Meise, Belgium, established in 2020. It focuses on developing immune-oncology therapeutics that address the relationship between vascular dysfunction and immune suppression in the treatment of solid tumors. The company has developed a target screening and assay platform that explores the interactions between tumor endothelial cells and perivascular macrophages. By understanding these cellular interactions, Montis Biosciences aims to create novel therapeutic strategies that enhance immune reactions against solid tumors, offering a new perspective for targeted cancer treatment.

reMYND NV is a biotechnology company based in Leuven, Belgium, focused on developing disease-modifying treatments for Alzheimer’s, Parkinson’s, diabetes, and other protein-misfolding disorders. The company is advancing several investigational compounds, including ReS19-T for Alzheimer’s and ReS39 for diabetes, as well as ReS3-T, which targets neuronal hyperactivity associated with Alzheimer’s and epilepsy. Additionally, reMYND operates a phenotypic screening platform aimed at discovering small molecule treatments that mitigate the toxicity of misfolded proteins such as Tau and Synuclein. The company also functions as a contract research organization (CRO), providing services that assess the in-vivo characteristics and effects of experimental therapies using proprietary mouse models. This CRO capability has enabled reMYND to support various pharmaceutical clients, including major companies in the United States, Europe, and Japan, by delivering critical proof-of-concept data for drugs in clinical development. Established in 2002, reMYND is committed to addressing the challenges posed by protein misfolding diseases through innovative research and development.

Porphyrio NV is a Belgium-based company that specializes in providing intelligent management systems for poultry farming, focusing on egg and broiler production. Its flagship products, Lay-Insight and Broiler-Insight, are designed to assist farm managers in the day-to-day operations by utilizing real-time data and advanced statistical algorithms. These systems enhance operational efficiency by transforming sensor data into actionable insights, enabling proactive decision-making and predictive analysis. Porphyrio's technology also includes features such as access control and video surveillance, and it can integrate with external ERP systems. The company serves a diverse range of poultry, including breeders, broilers, laying hens, and turkeys. As of November 2018, Porphyrio operates as a subsidiary of Evonik Industries AG.